Four months after new rules adopted by the U.S. Department of the Treasury foiled Pfizer Inc.’s plans to acquire Allergan plc in a $160 billion tax inversion deal, the New York-based pharmaceutical giant has moved on to pick up a cancer drug maker with four Am Law 100 firms in tow.

On Monday, Pfizer announced that it has agreed to acquire San Francisco-based Medivation—manufacturer of the prostate cancer treatment drug Xtandi—in an all-cash deal valued at $14 billion, including debt. Ropes & Gray, a longtime legal adviser to Pfizer, has once again snagged the lead role for Pfizer through M&A partner Christopher Comeau in New York.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]